GSA Capital Partners LLP bought a new position in Avantor, Inc. (NYSE:AVTR - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 80,841 shares of the company's stock, valued at approximately $800,000.
Several other institutional investors have also modified their holdings of AVTR. Royal Bank of Canada boosted its stake in Avantor by 104.3% during the first quarter. Royal Bank of Canada now owns 203,738 shares of the company's stock worth $3,302,000 after buying an additional 104,022 shares during the period. Empowered Funds LLC boosted its position in shares of Avantor by 40.3% during the 1st quarter. Empowered Funds LLC now owns 17,659 shares of the company's stock worth $286,000 after purchasing an additional 5,075 shares during the period. Cetera Investment Advisers boosted its position in shares of Avantor by 40.2% during the 2nd quarter. Cetera Investment Advisers now owns 40,289 shares of the company's stock worth $542,000 after purchasing an additional 11,543 shares during the period. Quantbot Technologies LP acquired a new stake in Avantor in the 2nd quarter valued at approximately $232,000. Finally, Arrowstreet Capital Limited Partnership raised its position in Avantor by 214.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company's stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.
Wall Street Analysts Forecast Growth
AVTR has been the topic of several research reports. Zacks Research raised Avantor from a "strong sell" rating to a "hold" rating in a research note on Thursday, April 30th. Wells Fargo & Company boosted their price target on shares of Avantor from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $13.00 target price on shares of Avantor in a research note on Thursday, July 30th. Sanford C. Bernstein started coverage on shares of Avantor in a report on Friday, June 26th. They set a "market perform" rating and a $10.50 target price on the stock. Finally, Barclays raised their price target on shares of Avantor from $7.00 to $8.00 and gave the company an "underweight" rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Avantor presently has an average rating of "Hold" and an average price target of $12.00.
Check Out Our Latest Research Report on AVTR
Avantor Stock Performance
Shares of AVTR opened at $13.36 on Wednesday. The stock has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $9.57. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The stock has a market capitalization of $9.04 billion, a PE ratio of -15.91, a PEG ratio of 10.29 and a beta of 0.89. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $15.93.
Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the company posted $0.24 earnings per share. The business's revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts predict that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.
Avantor Profile
(
Free Report)
Avantor, Inc NYSE: AVTR is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor's offerings are organized across two primary segments.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Avantor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.
While Avantor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.